EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake

Lukas Frischknecht, Jan Schaab, Eloi Schmauch, Ayla Yalamanoglu, Dennis D Arnold, Judith Schwaiger, Christiane Gruner, Ronny R Buechel, Daniel P Franzen, Antonios G A Kolios, Jakob Nilsson

Frontiers in Immunology · 2023

DOI: 10.3389/fimmu.2023.1286684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, 2023. Verfasst von Lukas Frischknecht und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland. Hauptthemen laut MEDLINE: Sarcoidosis, Myocarditis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immunosuppressive therapy for cardiac sarcoidosis (CS) still largely consists of corticosteroid monotherapy. However, high relapse rates after tapering and insufficient efficacy are significant problems. The objective of this study was to investigate the efficacy and safety of non-biological and biological disease-modifying anti-rheumatic drugs (nb/bDMARDs) considering control of myocardial inflammation assessed by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) of the heart.

Methods

We conducted a retrospective analysis of treatment response to nb/bDMARDs of all CS patients seen in the sarcoidosis center of the University Hospital Zurich between January 2016 and December 2020.

Results

We identified 50 patients with CS. Forty-five patients with at least one follow-up PET/CT scan were followed up for a mean of 20.5 ± 12.8 months. Most of the patients were treated with prednisone and concomitant nb/bDMARDs. At the first follow-up PET/CT scan after approximately 6.7 ± 3 months, only adalimumab showed a significant reduction in cardiac metabolic activity. Furthermore, comparing all serial follow-up PET/CT scans (143), tumor necrosis factor inhibitor (TNFi)-based therapies showed statistically significant better suppression of myocardial 18 F-FDG uptake compared to other treatment regimens. On the last follow-up, most adalimumab-treated patients were inactive (n = 15, 48%) or remitting (n = 11, 35%), and only five patients (16%) were progressive. TNFi was safe even in patients with severely reduced left ventricular ejection fraction (LVEF), and a significant improvement in LVEF under TNFi treatment was observed.

Conclusion

TNFi shows better control of myocardial inflammation compared to nbDMARDs and corticosteroid monotherapies in patients with CS. TNFi was efficient and safe even in patients with severely reduced LVEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoidosisMyocarditisHumansFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRetrospective StudiesRadiopharmaceuticalsStroke VolumeAdalimumabVentricular Function, LeftAdrenal Cortex HormonesInflammation

Stichwörter der Autor:innen

Anti-TNFSUVmaxadalimumabazathioprincardiac metabolic activitycardiac sarcoidosismyocardial 18F-FDG PET

Substanzen

Fluorodeoxyglucose F18RadiopharmaceuticalsAdalimumabAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland.
  • Broad Institute of MIT and Harvard, Cambridge, MA, United States.
  • Artturi Ilmari (A.I) Virtanen Institute, University of Eastern Finland, Kuopio, Finland.
  • Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.
  • Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.

Zitieren

APA

Frischknecht, L., Schaab, J., Schmauch, E., Yalamanoglu, A., Arnold, D. D., Schwaiger, J., Gruner, C., Buechel, R. R., Franzen, D. P., Kolios, A. G. A., & Nilsson, J. (2023). Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1286684

Vancouver

Frischknecht L, Schaab J, Schmauch E, Yalamanoglu A, Arnold DD, Schwaiger J, et al. Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1286684

BibTeX
@article{Frischknecht2023,
  author = {Frischknecht, Lukas and Schaab, Jan and Schmauch, Eloi and Yalamanoglu, Ayla and Arnold, Dennis D and Schwaiger, Judith and Gruner, Christiane and Buechel, Ronny R and Franzen, Daniel P and Kolios, Antonios G A and Nilsson, Jakob},
  title = {Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake},
  journal = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1286684}
}
Kostenlos starten →